Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EBITDA (2016 - 2025)

Historic EBITDA for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to -$1.9 million.

  • BioCorRx's EBITDA fell 1758.98% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.4 million, marking a year-over-year decrease of 1262.45%. This contributed to the annual value of -$5.1 million for FY2024, which is 3530.87% down from last year.
  • BioCorRx's EBITDA amounted to -$1.9 million in Q3 2025, which was down 1758.98% from -$1.4 million recorded in Q2 2025.
  • BioCorRx's EBITDA's 5-year high stood at -$816292.0 during Q4 2023, with a 5-year trough of -$1.9 million in Q3 2025.
  • Its 5-year average for EBITDA is -$1.2 million, with a median of -$1.1 million in 2022.
  • Per our database at Business Quant, BioCorRx's EBITDA surged by 5551.26% in 2021 and then plummeted by 7303.92% in 2024.
  • BioCorRx's EBITDA (Quarter) stood at -$1.3 million in 2021, then grew by 11.08% to -$1.2 million in 2022, then surged by 30.78% to -$816292.0 in 2023, then tumbled by 36.23% to -$1.1 million in 2024, then crashed by 74.83% to -$1.9 million in 2025.
  • Its EBITDA was -$1.9 million in Q3 2025, compared to -$1.4 million in Q2 2025 and -$934182.0 in Q1 2025.